OncoPharm

Latest Episodes:

Cycling thru the CDK Inhibitors Mar 01, 2018

Show notes

Abemaciclib's up-front approval provides an opportunity to review all 3 currently FDA-approved CDK 4/6 inhibitors. Dosing, drug interaction, and indication differences are discussed.

It's All Immunotherapy Nowadays Feb 23, 2018

Show notes

Durvalumab's FDA-approval for NSCLC and the supporting PACIFIC study are discussed, then the ASCO Immunotherapy Toxicity Management Guidelines (7:45) are reviewed. Also, a plug for patient support groups.

Apalutamide Feb 15, 2018

Show notes

Apalutamide's FDA-approval is discussed, including discussion of its drug interaction potential and a review of the SPARTAN study. Updates (18:15) from ASCO GU and DOAC use in cancer (23:50) also discussed.

Landmarks in Oncology Pharmacy: CMF Feb 09, 2018

Show notes

The Landmarks series continues with Bonadonna's classic adjuvant CMF regimen in breast cancer in a pre-tamoxifen & pre-ER/PR testing era. Discussion points include number needed to treat (NNT) to prevent recurrence and how chlorambucil was considered for the 'C' in CMF.

Foundations in Oncology Pharmacy: Doxorubicin Feb 02, 2018

Show notes

Overview of doxorubicin from its Italian origins to its Red Devil alias. Uses and toxicities also discussed, of course.

Updates in Oncology Pharmacy: Lu-177 Jan 26, 2018

Show notes

New Drug Approval: Lutetium-177-dotatate is discussed as well as updates to indications for denosumab (m. myeloma), afatinib, & olaparib.

Landmarks in Oncology Pharmacy: MOPP Jan 19, 2018

Show notes

The Landmarks series continues with DeVita's original MOPP (Hodgkin's Disease) publication from 1970. Discussion points include WBC monitoring, why cyclophosphamide isn't included, and wigs.

Foundations in Oncology Pharmacy: Cisplatin Jan 12, 2018

Show notes

The Foundations in Oncology Pharmacy series begins with the penicillin of oncology: cisplatin. Discussion of its history, current uses, & toxicities. Perfect for those new to oncology pharmacy.

Updates in Oncology Pharmacy: Adjuvant pertuzumab & nilotinib discontinuation (CML) Jan 05, 2018

Show notes

Review of recent FDA action re: oncology pharmacy including review of the APHINITIY trial and pertuzumab's subsequent approval in the adjuvant setting. Also, the nilotinib label change allowing for discontinuation in CML patients is discussed.

Landmarks in Oncology Pharmacy: Acute Leukemia in 1958 Jan 01, 2018

Show notes

In the 1st of the Landmarks series, we look back at a pivotal article published in Blood in 1958 on the treatment of acute leukemia.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected